1. Volume 49, Issue 4, Pages 666-674 (April 2006)
Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy- Naive Androgen Independent Prostate Cancer 
Robert Svatek, Pierre I. Karakiewicz, Michael Shulman, Jose Karam, Paul Perrotte, Elie Benaim 
European Urology 
Volume 49, Issue 4, Pages (April 2006)
DOI: /j.eururo
Copyright © 2005 Elsevier B.V. Terms and Conditions

2. Fig. 1
Kaplan-Meier estimates of AIPC-specific survival, overall and other-cause survival with 95% confidence intervals.
European Urology  , DOI: ( /j.eururo )
Copyright © 2005 Elsevier B.V. Terms and Conditions

3. Fig. 2
The effect (and its 95% confidence interval) of each predictor on log relative hazard of androgen insensitive prostate cancer-specific survival. All other remaining predictors are held constant.
European Urology  , DOI: ( /j.eururo )
Copyright © 2005 Elsevier B.V. Terms and Conditions

4. Fig. 3
Calibration plots for prediction of AIPC-specific survival at 12–60 months. Nomogram data are shown in the left hand column and recursive partitioning data are shown in the right hand column.
European Urology  , DOI: ( /j.eururo )
Copyright © 2005 Elsevier B.V. Terms and Conditions

5. Fig. 4 Nomogram predicting AIPC-specific survival.
PSA ADT init.: PSA at start of androgen deprivation therapy
ADT: androgen deprivation therapy
AIPC: androgen insensitive prostate cancer
Time ADT≥AIPC(M): Time from ADT to AIPC diagnosis.
12(M)AIPC-Spec.Surv. – probability of AIPC-specific survival at 12 months after AIPC diagnosis
24(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 24 months after AIPC diagnosis
36(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 36 months after AIPC diagnosis
48(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 48 months after AIPC diagnosis
60(M)AIPC-Spec.Surv – probability of AIPC-specific survival at 60 months after AIPC diagnosis
Instruction for physician: Locate the patient’s PSA at the time of androgen-deprivation therapy initiation (PSA at ADT init.) on the PSA at ADT init. axis. Draw a line straight upwards to the Points axis to determine how many points towards AIPC-specific survival the patient receives. Repeat this process for the other predictors, each time drawing a straight upward line to the Points axis. Sum the points for each predictor and locate this sum on the Total Points axis. Draw a line straight down to find the patient’s probability of AIPC-specific survival at 12, 24, 36, 48 and 60 months after androgen insensitive prostate cancer (AIPC) diagnosis, assuming he does not die of another cause first.
European Urology  , DOI: ( /j.eururo )
Copyright © 2005 Elsevier B.V. Terms and Conditions